BBCNEWS The Context June 4, 2024 19:46:00
Was licensed for use in the us earlier this month. it means that after years of trial failures, there are now two treatments that delay the relentless progression of alzheimer's. and surely that paves the way for better drugs down the line. our medical editor fergus walsh has spoken exclusively to one of the patients on the trial. hello. are you all right, mr colley? hi, yes. yes. i've got your donanemab here for you... mike colley has alzheimer's disease, yet the 80—year—old feels incredibly fortunate. i'm one of the luckiest people you'll ever meet. just for this. that's because he's bee...
Source: archive.org
